News
A Billion-Euro Market, Redefined
Germany's legal cannabis market has surpassed €1.15 billion in value, according to a new industry report from Business of Cannabis — a figure that cements the country's position as Europe's largest and most closely watched regulated cannabis economy. The milestone arrives at a complicated moment: the era of statutory health insurance reimbursement for cannabis prescriptions, which helped drive early patient adoption, is drawing to a close.
The confluence of these two developments — explosive market growth and the withdrawal of a key financial support mechanism — offers a revealing snapshot of where European cannabis policy is heading, and raises questions that extend well beyond Germany's borders.
Reimbursement's End: A Policy Turning Point
For several years, patients in Germany could have medical cannabis prescriptions reimbursed through their statutory health insurance funds under certain clinical conditions. That framework provided both legitimacy and accessibility, bringing cannabis into the mainstream of German healthcare in a way that few European jurisdictions had managed.
The withdrawal of routine reimbursement does not eliminate the medical cannabis market — the report's figures make that clear — but it does shift the financial burden back onto patients and, in some cases, private insurers. Industry analysts have described this as a maturation moment: a sector that once relied on institutional support is being tested on whether it can sustain itself through out-of-pocket consumer demand and the emerging adult-use framework introduced under Germany's partial legalisation legislation in 2024.
That legislation, which came into force in April 2024, permits adults to possess and grow limited quantities of cannabis for personal use, and establishes a framework for regulated social clubs. It does not yet include commercial adult-use retail, but the pressure to expand the model is growing — not least because the market data now suggests substantial consumer appetite exists independent of the medical channel.
What the Numbers Actually Tell Us
A market valued at over one billion euros is significant, but the composition of that figure matters. Germany's cannabis revenues have historically been concentrated in the pharmacy-dispensed medical segment, where price points are high and volumes are driven by a relatively small number of heavy users and chronic condition patients. The question now is whether the broader liberalisation measures, and eventually a commercial retail framework, will deepen the market by bringing in casual and recreational consumers — or whether regulatory friction will keep growth incremental.
For investors and operators across Europe, Germany remains the benchmark. Its regulatory decisions, pricing dynamics, and consumption data are watched as leading indicators for what other jurisdictions might expect when they move toward their own reform frameworks.
Relevance for Malta and the Mediterranean
Malta occupies a distinct position in this European conversation. As the first EU member state to legalise personal cannabis use and establish a regulated non-profit distribution model, it has pursued a harm reduction-centred approach that differs structurally from Germany's pharmacy and club-based systems. Where Germany leans on clinical infrastructure and a nascent social club model, Malta's framework centres on CHRAs — Cannabis Harm Reduction Associations — overseen by ARUC, the Authority on the Responsible Use of Cannabis.
The German market data is nonetheless instructive for Maltese policymakers and ARUC observers. The reimbursement question, for instance, touches directly on how medical cannabis patients are supported financially — a matter of ongoing discussion in Malta, where access to pharmaceutical-grade cannabis through the health system remains limited for many patients.
Sources within the local harm reduction community have pointed to Germany's experience as evidence that patient demand for cannabis does not simply evaporate when institutional support is reduced, but that it reshapes itself — sometimes in ways that are harder to monitor and regulate. For a small island jurisdiction like Malta, where ARUC is still building the evidentiary base for its regulatory decisions, this kind of real-world data from larger markets carries practical weight.
Europe Watching Closely
Beyond Malta, the broader European picture is one of cautious but accelerating movement. France is conducting a medical cannabis pilot. The Netherlands is running a regulated supply experiment. The Czech Republic has enacted personal use reforms. And the European Commission continues to receive pressure from member states and civil society organisations to harmonise the patchwork of national approaches.
Germany's billion-euro market figure will feature prominently in those conversations — both as an argument for liberalisation's economic potential and as a case study in the complexities that follow. The end of reimbursement, in particular, will be cited by advocates on both sides: by those who argue that cannabis should be treated like any other consumer product, and by those who insist that without healthcare integration, vulnerable patients are left behind.
The report does not resolve those tensions. But it does confirm that the European cannabis market has moved well past the point where these questions can be deferred.
Sources:
Business of Cannabis
Featured image: Photo by cottonbro studio on Pexels
Members Discussion